Evercore ISI initiated coverage on shares of Atreca (NASDAQ:BCEL) in a research note published on Monday morning, Benzinga reports. The firm issued an outperform rating and a $16.63 price objective on the stock.
Separately, Cowen reiterated a buy rating on shares of Avrobio in a research note on Monday.
NASDAQ:BCEL opened at $16.00 on Monday. Atreca has a 12 month low of $14.26 and a 12 month high of $20.00.
Atreca Company Profile
Atreca, Inc, a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.
Featured Article: Google Finance
Receive News & Ratings for Atreca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atreca and related companies with MarketBeat.com's FREE daily email newsletter.